Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide in CBF Leukemia
NCT03031262Phase 2Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2017
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tucidinostat in acute myeloid leukemia (AML) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Relapse-Free Survival Rate at 5 years. Started Feb 2017; status: active, not recruiting.
02
Drugs
tucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03031262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031262.